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ABSTRACT
Objective: Monoacylglycerol acyltransferase (MGAT) enzymes catalyze the synthesis of diacylglycerol from monoacylglycerol. Previous work has
suggested the importance of MGAT activity in the development of obesity-related hepatic insulin resistance. Indeed, antisense oligonucleotide
(ASO)-mediated knockdown of Mogat1 mRNA, which encodes MGAT1, reduced hepatic MGAT activity and improved glucose tolerance and insulin
resistance in high-fat diet (HFD)-fed mice. However, recent work has suggested that some ASOs may have off-target effects on body weight and
metabolic parameters via activation of the interferon alpha/beta receptor 1 (IFNAR-1) pathway.
Methods: Mice with whole-body Mogat1 knockout or a ﬂoxed allele for Mogat1 to allow for liver-speciﬁc Mogat1-knockout (by either a liverspeciﬁc transgenic or adeno-associated virus-driven Cre recombinase) were generated. These mice were placed on an HFD, and glucose
metabolism and insulin sensitivity were assessed after 16 weeks on diet. In some experiments, mice were treated with control scramble or
Mogat1 ASOs in the presence or absence of IFNAR-1 neutralizing antibody.
Results: Genetic deletion of hepatic Mogat1, either acutely or chronically, did not improve hepatic steatosis, glucose tolerance, or insulin
sensitivity in HFD-fed mice. Furthermore, constitutive Mogat1 knockout in all tissues actually exacerbated HFD-induced obesity, insulin sensitivity,
and glucose intolerance on an HFD. Despite markedly reduced Mogat1 expression, liver MGAT activity was unaffected in all knockout mouse
models. Mogat1 overexpression in hepatocytes increased liver MGAT activity and TAG content in low-fat-fed mice but did not cause insulin
resistance. Multiple Mogat1 ASO sequences improved glucose tolerance in both wild-type and Mogat1 null mice, suggesting an off-target effect.
Hepatic IFNAR-1 signaling was activated by multiple Mogat1 ASOs, but its blockade did not prevent the effects of either Mogat1 ASO on glucose
homeostasis.
Conclusion: These results indicate that genetic loss of Mogat1 does not affect hepatic MGAT activity or metabolic homeostasis on HFD and show
that multiple Mogat1 ASOs improve glucose metabolism through effects independent of targeting Mogat1 or activation of IFNAR-1 signaling.
Ó 2021 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) results from ectopic hepatic
lipid accumulation (steatosis) and is believed to be a key driver of
many metabolic abnormalities associated with obesity, including insulin resistance and diabetes [1,2]. In obesity, the liver is overloaded
with fatty acids from dietary intake, increased adipose tissue lipolysis,
and higher rates of de novo lipid synthesis [3e5]. The liver must
efﬁciently store these lipids as neutral triacylglycerol (TAG) to prevent
deleterious effects of toxic lipid intermediates, such as activation of
inﬂammation, endoplasmic reticulum (ER) stress, and insulin resistance [6].

There are two pathways of TAG synthesis in the liver: the glycerol-3phosphate (G-3-P) pathway and the monoacylglycerol O-acyltransferase (MGAT) pathway. These pathways converge at diacylglycerol (DAG); the sole precursor of TAG [7e9]. MGATs acylate
monoacylglycerol to form DAG and this enzymatic activity is encoded
by several genes including Mogat1, Mogat2, and Dgat1 in mice [10e
13]. The importance of MGAT activity in intestinal absorption of dietary
fat has long been studied [8,14]. Generally, the G-3-P pathway is
considered to be the primary route of TAG synthesis in tissues other
than the intestine, and the MGAT pathway is believed to be an auxiliary
pathway. We have recently demonstrated that Mogat1 is highly
expressed in adipocytes and may function to suppress aberrant
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lipolysis [15]. In addition, the expression and activity of the MGATs are
increased in humans and mouse models of NAFLD [16e20]. Suppression of hepatic and adipose tissue Mogat1 expression, through use
of antisense oligonucleotides (ASO), reduces hepatic MGAT activity and
improves hepatic insulin sensitivity and glucose metabolism without
affecting hepatic DAG or TAG levels in obese mice [17,18].
Second-generation ASOs are known to target multiple tissues,
including liver, adipose, and intestine, all of which have MGAT activity
[21]. Moreover, off-target effects of ASO treatment have also been
described [22]. McCabe et al. recently demonstrated weight loss,
adipocyte browning, and improvement in adipose tissue metabolism
by ASO treatment that was independent of target gene knockdown
[22]. These effects were mediated through the activation of interferon
alpha/beta receptor 1 (IFNAR-1) signaling in adipose-derived macrophages [22]. Thus, we sought to obtain rigorous and independent
conﬁrmation that hepatic Mogat1 plays an important role obesityrelated hepatic insulin resistance and metabolic abnormalities using
novel liver-speciﬁc and global Mogat1 knockout mice. Our data surprisingly suggest that multiple Mogat1 ASO sequences improve
glucose metabolism through MGAT1-independent mechanisms and
that the effects are not mediated through IFNAR-1 activation.
2. METHODS
2.1. Generation of mouse models
All mouse studies were approved by the Institutional Animal Care and
Use Committee of Washington University. Due to the resistance of
female mice to the effects of high fat diet (HFD), male mice in the
C57BL6/J background were used in all studies. Mice were group
housed and maintained on standard laboratory chow on a 12 h light/
dark cycle. At eight-weeks of age mice were placed on control low-fat
diet (LFD, Research Diets, 10 kcal, % fat matched sucrose, D12450J)
or HFD (Research Diets, 60 kcal % fat, D12492) for the durations
indicated. ASO treatments were performed as previously described
[17]. Brieﬂy, starting at 16 weeks on diet, mice were given twice
weekly intraperitoneal injections of ASO directed against Mogat1
(sequence #1: 50 -GATCTTGGCCACGTGGAGAT-3’ (20-mer), or
sequence #2: 50 -TGGCCACGTGGAGATACGAT-3’ (20-mer), where
indicated) or scramble control (Ionis, Pharmaceuticals, Inc., Carlsbad,
CA; 25 mg/kg body weight) for three weeks.
Embryonic stem (ES) cells used to generate Mogat1 whole-body
knockout and Mogat1 ﬂoxed mice were obtained from the Knockout
Mouse Consortium (KOMP, project# CSD35789) [15]. Brieﬂy, these ES
cells contained a Mogat1 allele wherein a cassette containing cDNAs
encoding LacZ and a neomycin-resistance locus was inserted just
upstream of Mogat1 exon 4 that was ﬂanked by LoxP sites. Mogat1
exon 4 encodes the HPHG catalytic site of MGAT1, and thus loss of this
exon will result in loss of its enzymatic activity. Resulting chimeric
offspring from ES cell injections were mated to C57BL6/J mice to
establish a line of constitutive whole-body Mogat1 knockout mice.
Other heterozygous whole-body knockout mice were crossed to
transgenic mice expressing Flp recombinase to remove the LacZ/Neo
cassette and generate the Mogat1 ﬂoxed line. These mice were then
crossed with mice expressing albumin promoter-driven Cre recombinase (Jackson Laboratory, B6.Cg-Speer6-ps1Tg (Alb-cre)21Mgn/J).
Control mice are considered Mogat1 ﬂoxed mice without the expression of the albumin promotor-driven Cre recombinase.
Acute liver-speciﬁc knockout mice were generated by retro-orbital
injection of Mogat1 ﬂoxed mice with 2.0  1011 genomic copies
(GC) of adeno-associated virus serotype 8 (AAV8) expressing Cre
recombinase under the control of human thyroid hormone-binding
2

globulin (TBG) promoter (Vector Biolabs, VB1724). Control mice
received AAV8 expressing enhanced green ﬂuorescent protein (eGFP)
under control of the same promoter (Vector Biolabs, VB1743). For
hepatic Mogat1 overexpression, eight-week-old male C57BL6/J mice
were given LFD or HFD for six weeks, then administered AAV8-TBGeGFP or AAV8-TBG-mouse-Mogat1 by retro-orbital injection (Vector
Biolabs, VB1743, custom refseq# BC106135) and continued on diet for
the times indicated.
In the IFNAR-1 inhibition study, HFD-fed male C57BL/6J mice were
obtained from Jackson Laboratory after 12 weeks of HFD feeding. After
acclimation and four additional weeks of HFD feeding, mice were
weight matched into four treatment groups. Mice were given scramble
ASO or ASOs targeting Mogat1 as described above. During each ASO
treatment, mice were also given intraperitoneal (IP) injections of IgG
control (BioCell InVivoIMAb, #BE0083, clone MOPC-21) or a monoclonal neutralizing antibody targeting interferon alpha/beta receptor 1
(IFNAR-1) (BioCell InVivoIMAb, #BE0241, clone MAR1-5A3) [23].
Antibody treatments were given as IP injections of 250 ug per mouse in
100 uL of dilution buffer (BioCell, InVivoPure Ph 6.5 Dilution Buffer,
#IP0065) twice a week for the ﬁrst two weeks of ASO treatment,
followed by three separate injections of 500 ug per mouse the third
week of ASO treatments.
Prior to sacriﬁce, mice were fasted for 4 h starting at 0900. Mice were
euthanized via CO2 asphyxiation. Blood was collected from venipuncture of the inferior vena cava into EDTA-coated tubes, and plasma
was removed by centrifugation. Liver and other tissues were immediately collected, ﬂash-frozen in liquid nitrogen, and stored at 80  C
until further use.
2.2. Histology and NAFLD scoring
Liver tissue was harvested as described in section 2.1. Immediately
following dissection, livers were ﬁxed in 10% buffered formalin for
48 h. Liver tissue was rinsed and stored in 70% EtOH until parafﬁn
embedding, sectioning, and staining with hematoxylin-eosin (H&E) in
the Anatomic and Molecular Pathology Core Labs at Washington University School of Medicine. H&E sections were used to determine
NAFLD activity score by a blinded independent clinical pathologist [24].
2.3. Metabolic phenotyping of mouse models
Glucose tolerance tests (GTTs) were performed in mice fasted for 5 h
starting at 0900. Mice were given an IP injection of glucose (1 g/kg
body weight dissolved in saline), and blood glucose was measured
from the tail using a One Touch Ultra glucometer (Life Scan, Inc.) at the
times indicated. For insulin tolerance tests (ITTs), mice were fasted for
4 h before IP injections of recombinant Humulin RÒ (0.75 U/kg body
weight in saline). Tolerance tests were performed one week apart to
allow the mice to recover starting at 15 and 16 weeks of diet or week
two and three of acute treatments. Body composition was determined
in fed mice using ECHO MRI. Because the whole-body null mice had
differences in body weights compared to WT mice, the tolerance tests
in these mice were dosed based on lean mass (1 g glucose/kg lean
mass and 1.5 U insulin/kg lean mass).
2.4. Liver lipids and plasma metabolites
Frozen liver pieces were homogenized with bead disruption in
phosphate-buffered saline (PBS, 100 mg/mL). Lipids were solubilized
in 1% sodium deoxycholate via vortexing and heating at 37  C for
5 min. Triglycerides and total cholesterol were measured enzymatically
using the Inﬁnity triglyceride and cholesterol colorimetric assay kits
(Thermo Fisher, TR22421 and TR13421) and normalized to mg tissue
(wet weight). Plasma insulin was determined by Singulex
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Immunoassay (Millipore Sigma) via the Washington University Core
Laboratory for Clinical Studies. Plasma ALT and AST were measured
using TECO Diagnostic liquid kinetic assays (A524 and A559).
2.5. mRNA isolation and quantitative polymerase chain reaction
(PCR)
Total liver RNA was isolated from frozen liver samples using RNA STAT
(Iso Tech, CS-502) according to the manufacturer’s protocol. RNA was
reverse transcribed into cDNA using Taqman high-capacity reverse
transcriptase (Life Technologies, 43038228). Quantitative PCR was
performed using Power SYBR green (Applied Biosystems, 4367659)
and measured on an ABI PRISM 7500 or ABI QuantStudio 3 sequence
detection system (Applied Biosystems). Results were quantiﬁed using
the 2DDCt method and shown as arbitrary units relative to control
groups. Primer sequences are listed in Supplemental Table 1.
2.6. Primary hepatocyte isolations
Primary hepatocytes were isolated as previously described [25].
Brieﬂy, 10- to 16-week-old female mice were given an overdose of
isoﬂurane prior to perfusions. The livers were perfused via catheterization of the hepatic portal vein and ﬂushed with 30 mL of HBSS (Ca2þ/
Mg2þ-free, 0.5 mM EGTA) prior to digestion with 20 mL of collagenase
solution Type IV collagenase (sigma S5138) at 1 mg/mL in DMEM
(serum free, 1 mM sodium pyruvate). Following perfusion, the livers
were removed and disrupted in the collagenase solution. Cells were
added to ice-cold complete DMEM (10% FBS, 1 mM sodium pyruvate,
100 U PenStrep, 0.25 mg/mL amphotericin b) and passed through a
50-mM ﬁlter prior to centrifugation at 50g  2 min. The supernatant
was removed, and hepatocytes were resuspended in complete DMEM
and washed two more times. Five hundred thousand cells were then
directly added to RNA STAT for RNA isolation and quantiﬁcation.
2.7. MGAT enzymatic assay
MGAT activity was determined as previously described [26]. Liver
tissue (50 mg/mL) was homogenized by probe sonicated in ice-cold
membrane buffer (50 mM TriseHCl pH 7.4, 1 mM EDTA, 250 mM
sucrose, and complete protease inhibitors table (Roche Diagnostics,
A32965)). Homogenates were clear of whole-cell debris by low-speed
centrifugation at 500g  10 min at 4  C. The resulting supernatants
were spun at 100,000 g  60 min at 4  C using a Beckman benchtop
ultra-centrifuge. The cytosolic fractions (supernatant) were removed,
and the membranes were reconstituted via pipetting in membrane
buffer without protease inhibitors. Proteins were quantiﬁed using the
bicinchoninic acid (BCA) assay according to the manufacturer’s protocols (Thermo Fisher, 23225). Fifty micrograms of membrane were
incubated in assay buffer (5 mM MgCl2, 1.25 mg/mL BSA, 200 mM
sucrose, 100 mM TriseHCl (pH 7.4)) containing 20 mM of [14C]oleoylCoA (American Radiolabeled Chemicals, ARC 0527), and 200 mM of
sn-2-oleoylglycerol (Caymen Chemical, 16537) for 10 min. The reaction was stopped with 50 mL of 1% phosphoric acid. Lipids were
extracted in 2:1 v/v % CHCl3:MeOH and separated by thin-layer
chromatography in hexane/ethyl ether/acetic acid (80:20:1, v/v/v %).
Samples were run against standards for oleic acid, 1, 3 diacylglycerol,
and triglyceride, and corresponding spots were scraped from the plate
and 14C-radioactivity was measured via scintillation counter. Backgrounds were calculated from reaction mixtures without membrane
fractions.
2.8. Statistical analysis
Data were analyzed using GraphPad Prism software. Independent and
paired T-tests, one-way analysis of variance (ANOVA), or factorial

ANOVAs were performed where appropriate. Secondary post-hoc
analysis found differences in groups using either Tukey or Sidek
multiple comparisons where appropriate. P < 0.05 was considered
signiﬁcant.
3. RESULTS
3.1. Liver-speciﬁc knockout of Mogat1
We generated mice with hepatocyte-speciﬁc deletion of Mogat1, and
the resulting offspring were outwardly normal on a standard chow diet.
When given ad libitum access to a 10% fat (low-fat diet, LFD) or 60%
fat (HFD), the mice gained weight similar to littermate ﬂ/ﬂ controls
(Figure 1A). Contrary to our previous studies showing a beneﬁcial
effect of Mogat1 ASOs on metabolic parameters in obese mice,
glucose and insulin tolerance was not different between genotypes on
LFD or HFD (Figure 1B,C). We conﬁrmed that Mogat1 expression was
markedly suppressed in Mogat1 ﬂ/ﬂ Alb-Cre þ livers and freshly
isolated primary hepatocytes (of note, Mogat1 expression drastically
decreases after hepatocyte isolation and plating, data not shown)
(Figure 1D,E). Hepatic TAG content increased with HFD but was similar
between genotypes (Figure 1F). In contrast to previous work with
Mogat1 ASO-treated mice, MGAT activity in isolated liver membranes
was not affected by Mogat1 knockout (Figure 1G and ref. [17]).
Therefore, gene expression of similar acyltransferases with known
MGAT activity (Mogat2, Dgat1) and DGAT activity (Dgat2) were
measured. Mogat2 was not signiﬁcantly increased in knockout mice,
while both Dgats increased with HFD but were unaffected by Mogat1
knockout (Figure 1H).
3.2. AAV8-mediated liver-speciﬁc knockout of Mogat1
To avoid possible compensation from chronic Mogat1 knockout, we
injected Mogat1 ﬂ/ﬂ mice with an AAV8-TBG-Cre or eGFP control after
16 weeks of HFD feeding and assessed glucose homeostasis three
weeks later (Figure 2). This paradigm was selected because three
weeks of Mogat1 ASO treatment after 16 weeks on diet is effective at
improving insulin sensitivity and glucose homeostasis [16,17]. After
three weeks, compared to GFP controls, AAV8-Cre knockout mice had
similar body weight and no differences in glucose or insulin tolerance
(Figure 2AeC). The AAV8-Cre reduced Mogat1 expression (Figure 2D).
Similar to constitutive Mogat1 liver-speciﬁc knockout, acute deletion of
hepatic Mogat1 did not alter liver TAG content and slightly increased
MGAT activity (Figure 2E,F). Gene expression of similar acyltransferases (Mogat2, Dgat1, Dgat2) were unaffected by Mogat1
knockout (Figure 2G) [10e13]. These data indicate that genetic
deletion of Mogat1 in the livers of diet-induced obese mice for 3 weeks
does not affect glucose or insulin tolerance, and may suggest
compensation from other enzymes with MGAT activity [11,12,27].
3.3. Mogat1 whole-body deletion
Mogat1 ASO treatment likely results in gene knockdown in multiple
tissues [18,21]. Thus, we generated Mogat1 whole-body null mice
(MOKO) to delete Mogat1 in all tissues (Figure 3). MOKO mice were
outwardly normal on standard chow diet. Unexpectedly, when given an
HFD, MOKO mice gained more total body weight than littermate wildtype (WT) control mice (Figure 3A,B). The heterozygous littermates had
an intermediate phenotype (data not shown). The increase in weight
gain was not attributed to increased adiposity as evidenced by fat mass
and percent adiposity in ECHO MRI and individual fat pad weights and
thus may be due to larger body size (Figure 3B and Supplemental
Fig. 1). Glucose tolerance was not affected by Mogat1 knockout
(Figure 3C). However, HFD-fed MOKO mice had reduced insulin
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Figure 1: Constitutive liver-speciﬁc Mogat1 deletion does not improve insulin sensitivity in mice. Male Mogat1 ﬂ/ﬂ mice and littermate Mogat1 ﬂ/ﬂ albumin Cre þ mice were fed
an LFD or an HFD starting at 8 weeks of age for 16 weeks. Mice were fasted for 4 h prior to sacriﬁce and tissue collection. A: HFD increased body weight in both groups. B,C: HFDfed mice have impaired glucose and insulin tolerance compared to LFD groups. D,E: Mogat1 gene expression is reduced in knockout liver and primary hepatocytes. F: HFD
increased liver TAG content in both genotypes. G: MGAT activity was not affected by diet or genotype. H: Gene expression of Mogat2, Dgat1, and Dgat2 were unaffected by Mogat1
knockout. Data are expressed as means  S.E.M, and signiﬁcance was assessed by two-way ANOVA with Sidak’s multiple comparison test, #p < 0.05 gene effect, and yp < 0.05
diet effect; n ¼ 5e10 for mouse studies. n ¼ 3e5 female mice for primary hepatocyte isolations and two-tailed Student’s t-test were performed, #p < 0.05 gene effect.

tolerance and increased plasma insulin concentrations, which could be
indicative of insulin resistance (Figure 3D,E). Mogat1 gene expression
was undetectable in livers of MOKO mice (Figure 3F) or in any other
tissue analyzed (data not shown). MOKO mice had similar TAG content
and MGAT activity (Figure 3G,H). Similar to the liver-speciﬁc knockout
models, MOKO mice had no increases in hepatic Mogat2, Dgat1, and
Dgat2 (Figure 3J).
3.4. Hepatic Mogat1 overexpression
We next aimed to determine whether overexpression of hepatic Mogat1
was sufﬁcient to promote hepatic steatosis, insulin resistance, and
deleterious effects on systemic glucose metabolism. We fed C57BL6/J
mice an LFD for six weeks then injected them with AAV8 expressing

4

either GFP or mouse Mogat1 under control of the hepatocyte-speciﬁc
TBG promoter and continued them on diet for an additional ten weeks
(Figure 4). Mogat1 overexpressing (OE) mice gained similar weight as
the GFP control-treated mice (Figure 4A). After 16 weeks (ten weeks of
overexpression), there was no difference in glucose or insulin tolerance
between groups (Figure 4B,C). Mogat1 gene expression was signiﬁcantly increased by the administration the AAV8-Mogat1 (Figure 4D).
MGAT1 overexpression increases liver TAG and MGAT activity.
(Figure 4E,F). Despite the increases in MGAT activity and hepatic TAG
content, Mogat1 overexpression did not alter liver histology or markers
of NAFLD progression, including liver cholesterol, NAFLD score, or
plasma alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) (Figure 4G and Supplemental Fig. 2).
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Figure 2: Acute liver-speciﬁc deletion of Mogat1 does not improve glucose or insulin tolerance in HFD-fed mice. Male Mogat1 ﬂ/ﬂ mice were fed an HFD starting at 8 weeks of
age. After 16 weeks, mice were given a retro-orbital injection of AAV8-TBG-GFP or Cre recombinase (2  1011 GC per mouse) and remained on diet for an additional 3 weeks. Mice
were fasted for 4 h prior to sacriﬁce and tissue collection. A: Acute liver-speciﬁc Mogat1 knockout did not affect body weight. B,C: Mogat1 knockout did not improve glucose or
insulin tolerance. D: Mogat1 knockout reduced Mogat1 gene expression in liver. E: Liver TAG content was not different among groups. G: Hepatic MGAT activity was increased by
acute Mogat1 knockdown in liver. Mogat1 knockout did not increase Mogat2, Dgat1, or Dgat2 gene expression in liver. Data are expressed as means  S.E.M., and two-tailed
Student’s t-tests were performed, #p < 0.05 gene effect, n ¼ 9.

Utilizing the same overexpression regimen, we investigated whether
Mogat1 overexpression exacerbates hepatic steatosis and insulin
resistance during HFD feeding (Figure 5). Similar to the LFD-fed mice,
Mogat1 overexpression did not affect body weight or glucose and insulin tolerance in HFD-fed mice (Figure 5AeC). Mogat1 gene
expression was signiﬁcantly increased by the AAV8-Mogat1-OE
treatment (Figure 5D). Unlike the LFD-fed mice, hepatic TAG and MGAT
activity were not different between groups (Figure 5E,F). Similarly,
Mogat1 overexpression did not alter liver histology or markers of
NAFLD progression in HFD-fed mice (Figure 5G and Supplemental
Fig. 2). Thus, we concluded that hepatic Mogat1 overexpression is
sufﬁcient to increase hepatic triglyceride accumulation on an LFD, but
not insulin resistance or systemic dysregulation of glucose
metabolism.
3.5. Mogat1 ASO treatment improves hepatic insulin sensitivity on
HFD
To conﬁrm our previous reports indicating that Mogat1 suppression by
ASO improves hepatic insulin sensitivity [17,18], we fed C57BL6/J
mice with an HFD. After 16 weeks, mice were weight-matched and
randomized to receive ASOs targeting either Mogat1 or scramble

control (Figure 6). As previously described [17], Mogat1 ASO treatment
did not affect body weight but reduced blood glucose and plasma
insulin levels on an HFD (Figure 6AeC). Mogat1 and Mogat2 expression was increased by the HFD and Mogat1 ASO treatments suppressed Mogat1 without affecting Mogat2 (Figure 6D,E). MGAT activity
was reduced without affecting liver TAG content (Figure 6F,G). Moreover, glucose tolerance was improved in mice using two different
Mogat1 targeting ASO sequences in HFD fed mice (Supplemental
Fig. 3). Together, these data conﬁrm our previous reports that multiple Mogat1 ASO sequences improve hepatic metabolism during an
HFD challenge.
3.6. Mogat1 ASO treatment improves glucose tolerance in Mogat1
whole-body null mice
Given the inability to reproduce the insulin-sensitizing effects of
Mogat1 ASOs in any of our genetic models, we tested whether Mogat1
ASO treatment improves glucose metabolism independent of Mogat1.
We treated MOKO mice, fed an HFD for 16 weeks, with multiple ASOs
targeting Mogat1 or scramble control (Figure 7 and Supplemental
Fig. 4). Remarkably, Mogat1 ASO treatment improved glucose tolerance in both MOKO and WT mice as indicated by the area under the
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Figure 3: Whole-body deletion of Mogat1 causes weight gain and insulin intolerance on an HFD. Male wild-type (WT) and littermate Mogat1 whole-body knockout (MOKO) mice
were fed an LFD or an HFD starting at 8 weeks of age for 16 weeks. Mice were fasted for 4 h prior to sacriﬁce and tissue collection. A: Mogat1 knockout mice gain (MOKO) more
weight on an HFD than littermate WT controls. B: ECHO MRI indicates MOKO mice have increased whole body mass, while compared to WT controls. C: Glucose tolerance (1 g/kg
lean mass) was not signiﬁcantly changed in MOKO mice. D,E: HFD-fed MOKO mice had signiﬁcantly impaired insulin tolerance (1.5 U/kg lean mass) and plasma insulin levels
compared to WT controls. F: Mogat1 gene expression was not detectable in MOKO mice on either diet. G: Liver TAG was increased by HFD but unaffected by genotype. H: MGAT
activity was unaffected by either diet or genotype. Data are expressed as means  S.E.M, and two-way ANOVA with Sidak’s or Tukey’s multiple comparison tests were performed
where appropriate, #p < 0.05 gene effect, yp < 0.05 diet effect. For the ITT, two-tailed Student’s t-test were performed, #p < 0.05 gene effect n ¼ 6e7.
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Figure 4: Hepatic Mogat1 overexpression increases liver TAG and MGAT activity in mice fed an LFD. Male C57BL6/J mice were fed an LFD at 8 weeks of age. After 6 weeks of diet
mice were injected (retro-orbital) with AAV8-TBG-GFP- or AAV8-TBG-Mogat1 (2  1011 GC per mouse) and remained on the diet for an additional 10 weeks. Mice were fasted for
4 h prior to sacriﬁce and tissue collection. A: AAV8-Mogat1-OE did not affect body weight. B,C: Mogat1 overexpression did not impair glucose or insulin tolerance. D: Mogat1 gene
expression was signiﬁcantly increased in AAV8-Mogat1-OE treated mice. E,F: Mogat1 overexpression increased both liver TAG and MGAT activity. G: H&E staining of liver sections
reveals similar histology between groups. Data are expressed as means  S.E.M., and two-tailed Student’s t-test were performed, #p < 0.05 gene effect, n ¼ 8e10.

curve for WT and at 30 min post-injection for the MOKO mice
(Figure 7A,B and Supplemental Figs. 4A and B). Mogat1 ASO treatment
lowered plasma insulin concentrations in WT mice and caused insulin
to trend lower in MOKO mice treated with Mogat1 ASO compared to
control ASO (Figure 7C). Mogat1 expression was nearly undetectable in
the livers of MOKO mice and was reduced by Mogat1 ASO only in WT
mice (Figure 7D and Supplemental Fig. 4C).
Recently, McCabe et al. demonstrated that ASO targeting TTC39B nonspeciﬁcally protects against diet-induced obesity and induces adipose
tissue browning through activation of a type I interferon alpha/beta
receptor 1 (IFNAR-1) in adipose tissue-derived macrophages even in
TTC39B knockout mice [22]. Although we did not observe any effect on

body weight associated with use of the Mogat1 ASO (Figure 6A), we
found that expression of several key indicators of IFNAR-1 signaling
(Oasl1, Iﬁt1, and IIﬁt2) were signiﬁcantly increased in MOKO mice
treated with Mogat1 ASOs (Figure 7E and Supplemental Fig. 4D). The
Mogat1 ASO also tended to increase the expression of these genes in
WT mice, while Ifnar1 gene expression was unchanged (Figure 7E and
Supplemental Fig. 4D).
3.7. IFNAR-1 blockade does not prevent improvements in glucose
homeostasis in Mogat1 ASO treated mice
To determine whether the increase in IFNAR-1 activation in response to
Mogat1 ASO treatment drives the improvements in glucose
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Figure 5: Hepatic Mogat1 overexpression does not increase liver TAG and MGAT activity in mice fed an HFD. Male C57BL6/J mice were fed HFD at 8 weeks of age. After 6 weeks
of diet, mice were injected (retro-orbital) with AAV8-TBG-GFP- or AAV8-TBG-Mogat1 (2  1011 GC per mouse) and remained on the diet for an additional 10 weeks. Mice were
fasted for 4 h prior to sacriﬁce and tissue collection. A: AAV8-Mogat1-OE did not affect body weight. B,C: Mogat1 overexpression did not impair glucose or insulin tolerance. D:
Mogat1 gene expression was signiﬁcantly increased in AAV8-Mogat1-OE treated mice. E,F: Mogat1 overexpression did not affect liver TAG and MGAT activity. G: H&E staining of
liver sections reveals similar histology between groups. Data are expressed as means  S.E.M. and two-tailed Student’s t-test were performed, #p < 0.05 gene effect, n ¼ 8e10.

metabolism, we injected ASO treated mice with a IFNAR-1 neutralizing
antibody or IgG control during an HFD challenge (Figure 8) [22,23]. We
repeated the previous observation that this Mogat1 ASO sequence
improved glucose tolerance and lowered plasma insulin in HFD-fed
mice (Figure 8A,B), but co-treatment with IFNAR-1 neutralizing antibody (INFAR1-Ab) did not block the improvements in glucose tolerance
nor plasma insulin concentrations in Mogat1 ASO-treated mice
(Figure 8AeC). Mogat1 ASO treatment suppressed liver Mogat1 gene
expression in IFNAR-1 neutralizing antibody-treated mice (Figure 8D).
Mogat1 ASO treatment did not signiﬁcantly activate IFNAR-1responsive genes in the livers of IgG-treated mice (Figure 8D) All of
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these genes were lowered by use of the INFAR1-Ab (Figure 8D).
Mogat1 ASO treatment also suppressed Mogat1 gene expression in
epididymal white adipose tissue (WAT) (Figure 8E) but did not increase
most INFAR-1 responsive genes in adipose tissue (Figure 8E). Lastly,
Mogat1 ASO treatment did not affect the expression of the WAT
browning markers, Ucp1, Ppargc1a, or Arb2, which is in contrast to
previous work (Figure 8F and ref [22]). In fact, Arb2 was increased in
mice treated with INFAR1-Ab regardless of which ASO mice received
(Figure 8F).
Alternatively, our second ASO sequence targeting Mogat1 had only
modest effects on glucose tolerance and plasma insulin levels that
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Figure 6: Mogat1 antisense oligonucleotide (ASO) treatment improves insulin sensitivity in HFD fed mice. Male C57BL6/J mice were fed an HFD starting at 8 weeks of age. After
16 weeks of diet, mice were injected (intraperitoneally) twice weekly with ASOs targeted against Mogat1 or scramble control (25 mg/kg) for 3 weeks. Mice were fasted for 4 h prior
to sacriﬁce and tissue collection. A: Body weight was not affected by Mogat1 ASO treatment. B,C: Mogat1 ASO treatment reduced blood glucose and plasma insulin levels in mice
fed an HFD. Gene expression was normalized to LFD-fed mice given scramble control. D: Hepatic Mogat1 gene expression was increased in HFD-fed mice and signiﬁcantly reduced
by Mogat1 ASO treatment E: Mogat2 gene expression was increased in HFD-fed mice. F,G: Hepatic MGAT activity was signiﬁcantly reduced by Mogat1 ASO treatment without
affecting liver TAG. Data are expressed as means  S.E.M., and two-tailed Student’s t-test or one-way ANOVA with Tukey’s multiple comparison test were performed where
appropriate, #p < 0.05 ASO effect, yp < 0.05 diet effect; n ¼ 5e10.

were unaffected by the INFAR1-Ab treatment (Supplemental Figs. 5Ae
C). Similar reductions of Mogat1 expression were observed in both liver
and adipose tissue. However, the second sequence induced IFNAR-1
signaling in both liver and adipose tissue of IgG-treated mice, and
these affects were suppressed by INFAR1-Ab treatment (Supplemental
Figs. 5D and E). Finally, the second sequence induced epididymal Upc1
expression (Supplemental Fig. 5F). These data indicate that multiple
Mogat1 ASO treatments non-speciﬁcally improve glucose metabolism,
and this effect is not mediated through the previously implicated
mechanism of IFNAR-1 activation [22].
4. DISCUSSION
Increased intrahepatic lipid content is tightly and mechanistically
linked to development of insulin resistance and systemic metabolic
abnormalities. Previous work by our group and others using RNA
interference approaches has demonstrated that knocking down
expression of Mogat1 in the livers of obese mice with hepatic
steatosis dissociates liver fat from insulin resistance and improves
glucose homeostasis [17,18,20,28]. In the present study, we
knocked out Mogat1 speciﬁcally in hepatocytes, both chronically and
acutely, and also generated a global Mogat1 knockout, but did not
observe any improvements in glucose homeostasis or insulin
sensitivity in diet-induced obese mice. Hepatic Mogat1

overexpression was sufﬁcient to increase hepatic MGAT activity and
TAG content, but only in LFD-fed mice, and did not result in insulin
resistance or glucose intolerance. Although we reproduced our
previous ﬁndings to demonstrate that multiple Mogat1 ASOs improve
glucose tolerance in obese mice, we also conclusively demonstrate
that these ASOs still improve metabolic homeostasis in mice with
global Mogat1 deletion. Lastly, we conﬁrm that these improvements
were not due to increased activation of IFNAR-1 as recently reported
for an ASO against TTC39B [22]. Collectively, these data suggest that
Mogat1 ASO treatment improves glucose homeostasis and insulin
sensitivity independently of knocking down Mogat1 expression and
by mechanisms that remain to be elucidated.
The development of technologies for in vivo RNA interference
through use of modiﬁed oligonucleotides has been a boon to hepatology and related disciplines. The ease of administration and livertrophic nature of these designer oligonucleotides has allowed researchers to suppress the expression of a variety of genes in the
liver and also led to clinically-approved approaches to treat metabolic disease [29,30]. Furthermore, in humans, unlike murine
models, ASO treatment does not increase clinical indicators of liver
and kidney injury [31] and next-generation ASO technology (GalNAc
conjugation) has increased potency and reduced inﬂammation in the
livers of mice, although their effects on off-target issues remains to
be determined [21,32].
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Figure 7: Mogat1 ASO treatment improves glucose tolerance in whole-body Mogat1 null mice on an HFD. Male wild-type (WT) and littermate Mogat1 whole-body knockout (MOKO)
mice were fed an HFD starting at 8 weeks of age. After 16 weeks of diet, mice were injected (intraperitoneal) twice weekly with ASOs targeted against Mogat1 or scramble control
(25 mg/kg) for 3 weeks. Mice were fasted for 4 h prior to sacriﬁce and tissue collection. AeC: Mogat1 ASO treatment improves glucose tolerance and AUC independently of Mogat1
expression and lowers plasma insulin in WT mice. D: Mogat1 gene expression was reduced by ASO treatment and nearly absent in MOKO livers. E: Gene expression markers of
interferon type-1 alpha/beta signaling are increased in Mogat1 ASO treated MOKO mice on HFD. Data are expressed as means  S.E.M, and two-way ANOVA with Sidak’s or
Tukey’s multiple comparison test were performed where appropriate #p < 0.05 from scramble ASO yp < 0.05 from WT controls; n ¼ 5e7.

We were quite ﬂummoxed when characterizing the phenotype of mice
lacking Mogat1 in liver by the inability to phenocopy our previously
reported phenotypes obtained using ASOs [17,18,26] or work by other
groups using adenoviral-driven expression of shRNA [20,28]. We
considered a number of possibilities to explain this. It is likely that
genetic deletion of Mogat1 leads to compensatory changes in other
enzymes that have MGAT activity, since ASO treatment leads to
reduced MGAT activity in the liver [17], whereas MGAT knockout either
acutely or chronically does not (Figures 1e3). Another possibility is
that the Mogat1 ASO was mediating its effects on a tissue other than
liver. Brandon et al. recently reported that that liver-speciﬁc KO of
protein kinase C ε (PKCε) did not phenocopy previous ASO work
conducted in rats and found instead that deletion of PKCε in adipose
tissue, which is often targeted by ASOs as well, produced an insulinsensitive phenotype [33,34]. However, our studies with adipocytespeciﬁc Mogat1 KO mice (manuscript in preparation) or with the
global MOKO mice did not reveal an insulin-sensitive phenotype. A
caveat to this is that we did not assess the effects of a combined
conditional Mogat1 knockout in adipocytes and liver, two tissues primarily targeted by the Mogat1 ASO, without deletion in other tissues
that may have compensatory effects. This will require further
consideration, but the observation that these ASOs have beneﬁcial
effects in MOKO mice suggests that the effects of the ASO is likely
disconnected from the suppression of Mogat1 expression. Taken
together with previous work, these studies demonstrate the importance of using rigorous and complementary controls when employing
ASOs to study intermediary metabolism and insulin sensitivity.
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It is now clear that Mogat1 ASOs elicit their effects even in the absence
of Mogat1 expression. In this work and in previous studies, we have
used multiple ASO sequences targeting Mogat1 with similar effects on
glucose metabolism, and these effects do not appear to be due to
silencing another gene from off-target interactions with RNA. The
present results parallel another recent paper that showed that ASOs
targeting TTC39B (T39) still elicited metabolic beneﬁts in global T39 KO
mice [22]. McCabe et al. [22] demonstrated in their model that ASO
treatment activated an interferon signaling pathway as indicated by an
induction of IFNAR-1 responsive genes (Oasl1, Iﬁt1, and Iﬁt2) that led
to adipocyte browning and the mice to lose weight. Exactly how the
interferon response is activated by ASO, how this occurs in the KO in
the absence of target RNA, and why the scramble control ASO does not
provoke the same response remains unclear. Although we did not
observe weight loss in our studies, Mogat1 ASO treatment in MOKO
mice stimulated the expression of Oasl1, Iﬁt1, and Iﬁt2 in liver. These
responses were strikingly exaggerated in MOKO mice but in the WT
mice, and we can only speculate that the lack of target RNA leads to
higher non-hybridization dependent toxicity noted for many ASOs [35],
while the scramble ASOs are designed to have minimal toxicities [21].
The activation of IFNAR-1 signaling may be consistent with our
previous work demonstrating that Mogat1 ASO exacerbates hepatic
inﬂammation on a diet that induces nonalcoholic steatohepatitis,
including components of interferon signaling [18,22]. While IFNAR-1
signaling activates a multitude of signaling pathways that could
plausibly affect glucose metabolism and insulin sensitivity [36], we
were unable to prevent the improvements in glucose metabolism
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Figure 8: Type I interferon alpha/beta receptor 1 neutralizing antibody (INFAR1-Ab) prevents inﬂammation without affecting glucose tolerance. Male C57BL6/J mice were fed an
HFD starting at 8 weeks of age. After 16 weeks of diet, mice were injected (intraperitoneal) twice weekly with ASOs targeted against Mogat1 or scramble control (25 mg/kg) with
an INFAR-1 neutralizing antibody (INFAR1-Ab) or IgG control (250 mg per mouse twice a week for weeks 1 and 2 and 500 mg per mouse 3 times for week 3). Mice were fasted for
4 h prior to sacriﬁce and tissue collection. AeC: Mogat1 ASO treatment improves glucose tolerance and lowers plasma insulin despite INFAR1-Ab treatment. D: Liver Mogat1 gene
expression was reduced by Mogat1 ASO treatment in the INFAR1-Ab treated mice and liver gene expression markers of interferon signaling are lowered by INFAR1-Ab treatment. E:
Epididymal Mogat1 gene expression was decreased by Mogat1 ASO treatment. Epididymal gene expression markers of interferon signaling were not increased by Mogat1 ASO
treatment. F: Expression of adipose browning genes were not affected by Mogat1 ASO treatment. Data are expressed as means  S.E.M and two-way ANOVA with Sidak’s or
Tukey’s multiple comparison test where appropriate, #p < 0.05 from Scramble ASO yp < 0.05 from IgG controls; n ¼ 7.

by blocking IFNAR-1 activation with an antibody. Thus, IFNAR-1 activation is not the mechanism for improved glucose and insulin tolerance
in response to Mogat1 ASO. However, we should note that the effects
of the neutralizing antibody were not assessed in the MOKO mice,

which have a greater inﬂammatory response to Mogat1 ASO. It is
possible that the antibody could have an effect in MOKO mice, but
given the complete lack of effect in WT mice, we feel that it is unlikely
that it will. The mechanism by which Mogat1 ASO elicits beneﬁcial
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metabolic effects, even in the absence of Mogat1 RNA, will require
further study.
Based on previous work with the Mogat1 ASOs [17,18,26], we were
surprised to ﬁnd that genetic deletion of Mogat1 in the liver did not affect
hepatic MGAT activity. Our targeted allele deletes exon 4 of the Mogat1
gene, which encodes the catalytic domain (HPHG), and we have previously shown that this effectively deletes all MGAT1 protein [15].
Moreover, the lack of effect on hepatic MGAT activity is consistent with
previous work by another group with an independently-generated KO
mouse showing that global Mogat1 KO mice do not have deﬁcits in
hepatic MGAT activity [37]. Several acyltransferase enzymes exhibit
MGAT activity, including MGAT2 and DGAT1, and the observation that
genetic loss of MGAT1 in the liver did not affect MGAT activity could
indicate that the other MGAT enzymes are the primary source of MGAT
activity in the liver [10e13,15]. It is known that MGAT2 has a higher
speciﬁc activity than MGAT1, and in many of the current studies, Mogat2
was upregulated by HFD feeding. Our previous work has shown that
adipocyte-speciﬁc Mogat1 KO mice exhibit reduced adipose tissue
MGAT activity [15], which may be consistent with the very low
expression of Mogat2 in adipose tissue. While we did not detect
increased expression of the known MGAT enzymes in any of our genetic
models [10e13], we cannot rule out post-transcriptional mechanisms,
including post-translational modiﬁcations that enhance activity.
5. CONCLUSIONS
Here, we provide evidence that multiple Mogat1 ASOs improve
whole-body metabolism through Mogat1-independent effects. Liverspeciﬁc Mogat1 ablation does not improve insulin resistance in HFDfed mice, as observed with Mogat1 ASO treatments [17,18].
Moreover, we show novel evidence that whole-body Mogat1 deletion
leads to insulin resistance in the context of diet-induced obesity.
Finally, we provide preliminary evidence that Mogat1 ASOs improve
glucose intolerance even in global Mogat1 KO mice. These ﬁndings
also demonstrate that careful consideration should be given for using
ASOs to target gene suppression, including use of genetic knockout
models, in metabolic studies that could be affected by these offtarget effects.
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